Revium Rx. Share Price

Stocks

Real-time OTC Markets 08:13:00 05/08/2025 pm IST			5-day change	1st Jan Change
0.5200 ^USD	+73.33%		-63.64%	-

14/08	Revium Rx. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
22/06	Revium Rx. Announces Resignation of Inna Martin from Director, Chief Operating Officer and President, Effective June 16, 2026	CI

Market Cap	8.68Cr 7.76Cr 7.24Cr 6.58Cr 12Cr 840.07Cr 12Cr 87Cr 34Cr 427.24Cr 33Cr 32Cr 1.37TCr	P/E 2024	-11.7x	P/E 2025	-2.35x
Enterprise Value	8.42Cr 7.53Cr 7.02Cr 6.38Cr 12Cr 814.84Cr 12Cr 84Cr 33Cr 414.4Cr 32Cr 31Cr 1.33TCr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

14/08	Revium Rx. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
22/06	Revium Rx. Announces Resignation of Inna Martin from Director, Chief Operating Officer and President, Effective June 16, 2026	CI
01/06	Revium Rx. Announces CFO Changes, Effective May 27, 2026	CI
15/05	Revium Rx. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Revium Rx. Appoints Amir Avraham as Permanent Chief Executive Officer, Effective as of February 1, 2026	CI
21/04	Revium Rx. Appoints Shlomi Schwartzblat as Director and Chairman of the Board, Effective April 14, 2026	CI
01/04	Revium Rx. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
31/03	Revium Rx. Auditor Raises 'Going Concern' Doubt	CI
17/01	Revium Rx. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
21/25/21	Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections	CI
04/25/04	Revium Rx. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/25/14	Revium Rx. has filed an IPO in the amount of $5 million.	CI
04/25/04	Revium Recovery Inc. completed the acquisition of LipoVac, Ltd.	CI

21/25/21	Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections	GL
05/25/05	Revium Rx (RVRC) Completes Acquisition of LipoVation Ltd.	GL
21/22/21	Revium Recovery, Inc. Announces Letter of Intent to Acquire LipoVac Ltd	AQ
20/22/20	Revium Recovery, Inc. Announces Letter of Intent to Acquire LipoVac Ltd.	AQ
18/20/18	Correction: REVIUM RECOVERY ACQUIRES ANTI-ADDICTION REHABILITATION BUSINESS	GL

Manager	Title	Age	Since
Amir Avraham CEO	Chief Executive Officer	-	22/05/2025
Igor Bluvstein DFI	Director of Finance/CFO	46	27/05/2026
Inna Martin CEO	Chief Executive Officer	51	-

Director	Title	Age	Since
Inna Martin BRD	Director/Board Member	51	-
Matti Munk BRD	Director/Board Member	-	-
Yoram Druker BRD	Director/Board Member	-	-

	2024	2025
Net sales	-	-
Net income	-35.05L -31.32L -29.22L -26.54L -49.98L -34Cr -50.36L -3.51Cr -1.37Cr -17Cr -1.32Cr -1.29Cr -55Cr	-1.34Cr -1.2Cr -1.12Cr -1.02Cr -1.92Cr -130.1Cr -1.93Cr -13Cr -5.26Cr -66Cr -5.05Cr -4.94Cr -212.7Cr
Net Debt	-52.78L -47.16L -44L -39.96L -75.27L -51Cr -75.83L -5.29Cr -2.07Cr -26Cr -1.98Cr -1.94Cr -83Cr	-26.09L -23.31L -21.75L -19.75L -37.21L -25Cr -37.48L -2.61Cr -1.02Cr -13Cr -97.95L -95.83L -41Cr

Employees

Sector